Transgene is a fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. Our expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials.

 

Four products are currently in clinical development: TG4010 having completed phase II trials, TG4001/RG3484 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial.

 

Transgene has concluded strategic agreements with two major pharmaceutical companies... >>> READ MORE

 
NEWS


Products
Cancers
TG4010 TG4023Noref
Infectious diseases
TG4040 TG4001/R3484
PUBLICATIONS